AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 111 min read$IRTC

Blackford Quentin S. sold $3.3M of IRTC

Blackford Quentin S. (President and CEO) sold 26,859 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($3.35M total) on 2026-08-10.

Original reporting
SEC EDGAR · Blackford Quentin S.
Published Aug 11, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but the disclosure alone does not change the company’s operating outlook.

02

Market read

A new insider sale of roughly $3.35M was reported, which can slightly influence sentiment but lacks fundamental catalysts in the text.

03

What to watch

The article notes no 10b5-1 plan, but it still provides no stated reason for the sale, limiting inference about future performance.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC CEO Blackford Quentin S. sold 26,859 shares in an open-market transaction for about $3.35M, per a new Form 4 filing.

Expected impact

Likely limited, short-lived impact unless paired with other negative news.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new guidance, financial results, or a change in business outlook.

Market effects

Sector

Minimal, as this is a routine insider sale with no sector-wide signal in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be driven by diversification or pre-planned liquidity needs, so it may not reflect bearish fundamentals.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider sale by its President and CEO.

  • insider
    Blackford Quentin S.

    President and CEO who sold 26,859 shares at $124.6514 on 2026-08-10.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 7
MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

hoodline.com3 min
OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min